# Shenzhen Salubris Pharmaceuticals Co. trials: 42 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials with Shenzhen Salubris Pharmaceuticals Co., Ltd. as lead sponsor, 15 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Shenzhen Salubris Pharmaceuticals Co., Ltd.: 42 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/shenzhen-salubris-pharmaceuticals-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 15
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923357 | A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, T2DM | 364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923357) |
| October 20, 2026 | NCT07884461 | The First-in-Human Study of GW906 Injection | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Hypertension | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884461) |
| October 19, 2026 | NCT07879755 | An Extension Trial of GW 906 in Participants With Essential Hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Not applicable | Recruiting | Hypertension | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879755) |
| September 23, 2026 | NCT07835984 | A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or... | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Hypertension | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07835984) |
| September 23, 2026 | NCT07835971 | A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Active not recruiting | Hypertension | 319 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07835971) |
| August 27, 2026 | NCT07790120 | A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including... | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 3 | Completed | Uncontrolled Hypertension, Resistant Hypertension | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790120) |
| August 4, 2026 | NCT07745114 | SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 1 | Active not recruiting | Healthy Participants, Elevated Lp(a) | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745114) |
| July 27, 2026 | NCT07729475 | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of... | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Elevated Lipoprotein(a) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729475) |
| July 23, 2026 | NCT07722299 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 1 | Not yet recruiting | Hyperlipidemia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722299) |
| July 21, 2026 | NCT07716618 | A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD) | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Active not recruiting | Chronic Kidney Disease | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07716618) |
| July 15, 2026 | NCT07704697 | Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 3 | Completed | Essential Hypertension | 346 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704697) |
| July 15, 2026 | NCT07704684 | Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 3 | Completed | Essential Hypertension | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704684) |
| June 17, 2026 | NCT07654140 | A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Recruiting | Uncontrolled Hypertension | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654140) |
| June 15, 2026 | NCT07647133 | A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Chronic Kidney Disease | 249 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647133) |
| June 12, 2026 | NCT07646535 | A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Primary Aldosteronism | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646535) |
| May 12, 2026 | NCT07579936 | A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Recruiting | Postmenopausal Women With Osteoporosis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579936) |
| March 20, 2026 | NCT07486453 | Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 1 | Not yet recruiting | Primary Hypertension | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486453) |
| February 3, 2026 | NCT07384104 | Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 1 | Enrolling by invitation | Osteoporosis | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07384104) |
| December 19, 2025 | NCT07295418 | A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 3 | Completed | Hyperlipidemias | 618 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07295418) |
| December 12, 2025 | NCT07278830 | A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Completed | Hypercholesterolemia and Mixed Dyslipidemia | 214 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07278830) |
| November 28, 2025 | NCT07253584 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in... | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 3 | Completed | Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia | 720 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07253584) |
| September 16, 2025 | NCT07174830 | Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 4 | Recruiting | Healthy Participants | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07174830) |
| July 23, 2025 | NCT07079579 | Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 4 | Not yet recruiting | Renal Anemia in Non-dialysis Chronic Kidney Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07079579) |
| July 4, 2025 | NCT07051603 | SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Uncontrolled Hypertension | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07051603) |
| June 22, 2025 | NCT07030504 | To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 1 | Active not recruiting | Pharmacokinetics | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07030504) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 1 |
| Phase 2 | 11 |
| Phase 3 | 14 |
| Phase 4 | 2 |
| Not applicable | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 17 |
| Not yet recruiting | 9 |
| Recruiting | 6 |
| Unknown | 5 |
| Active not recruiting | 4 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertension | 7 |
| Essential Hypertension | 5 |
| Diabetes Mellitus, Type 2 | 4 |
| Hyperlipidemias | 3 |
| Anemia | 3 |
| Osteoporosis, Postmenopausal | 2 |
| Hypercholesterolemia | 2 |
| Renal Insufficiency, Chronic | 2 |
| Renal Insufficiency | 2 |
| Hyperaldosteronism | 1 |
| Coronary Disease | 1 |
| Peripheral Arterial Occlusive Disease 1 | 1 |
| Chronic Limb-Threatening Ischemia | 1 |
| Atherosclerosis | 1 |
| Osteoporosis | 1 |
| Peripheral Arterial Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [B2B oil and gas extraction companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-extraction-companies/united-states)
- [Financial services firms in the United States](https://specstream.ai/data/businesses/financial-services-firms/united-states)
- [Otology practices in the United States](https://specstream.ai/data/businesses/otology-practices/united-states)
- [Video production companies in the United States](https://specstream.ai/data/businesses/video-production-companies/united-states)
- [Corporate gift suppliers in the United States](https://specstream.ai/data/businesses/corporate-gift-suppliers/united-states)
